ESMO Blockbuster | General Assembly: First-line immune monotherapy significantly improves OS in patients with poor prognosis in NSCLC
Time of Update: 2022-09-21
At plenary session III, Professor Siow Ming Lee presented the results of the Phase III IPSOS study, which suggested that first-line immune monotherapy improve outcomes in patients with poor prognosis (ECOG PS≥2).
Ferrero Group commits to 100% compostable, recyclable packaging by 2025
Time of Update: 2022-08-18
". " Ferrero's new commitment to packaging improvements will continue to drive the Group to continuously optimize its outer packaging footprint, aligning it with the company's development strategy to reduce its environmental impact from raw materials, production plants, logistics, and even the entire value chain .
AACR treatment of bladder cancer, bicyclic peptide conjugate therapy achieves 50% objective response rate
Time of Update: 2022-06-18
▲Characteristic comparison of bicyclic peptides with small molecules and antibodies (Image source: Bicycle Therapeutics' official website) In this clinical trial, patients with solid tumors who had received an average of 3 previous treatments received different doses of BT8009, of which 49% for urothelial carcinoma patients .
Are Pfizer Paxlovid and Merck Molnupiravir cost-effective
Time of Update: 2022-06-11
3 Hospital shared clinical cases of antiviral treatment for patients with COVID-19 (Omicron), including the use of Pfizer's oral novel coronavirus small molecule drug Paxlovid (Nematavir/ritonavir).
Time of Update: 2022-04-08
Thin layer plate silica gel G plateDeveloping solvent chloroform - methanol - formic acid (5:1: 0.
1)Check under UV lamp (254nm)2.
Thin layer plate silica gel G plateDeveloping solvent ethyl acetate - formic acid (10:0.
"Cell": Canada develops new inhaled new crown vaccine, protective effect is better than intramuscular vaccine
Time of Update: 2022-03-06
▲ Schematic diagram of the study (Image source: Reference ) The researchers also pointed out that due to the effectiveness of targeting the lungs and upper respiratory tract, this inhaled vaccine can reduce the dose required each time, even as low as intramuscular injection doses 1% of that would achieve the same level of protection .
Key data of Livzon Pharma's phase III clinical trial of recombinant novel coronavirus fusion protein vaccine sequential strengthening
Time of Update: 2022-03-06
issued an announcement stating that the "recombinant novel coronavirus fusion protein vaccine" ("V- 01”) has completed the interim master data analysis of the Sequentially Strengthened Phase III clinical trial, and obtained key data .
The "involution" of the caprolactam industry has intensified
Time of Update: 2022-01-09
In 2021, the overall operating rate of the caprolactam industry will gradually decline, especially since the second half of the year, as the cost pressure of enterprises increases and production profits decline, coupled with the national energy consumption "dual control" and power curtailment policies, caprolactam enterprises have stopped overhauling more .
The initial treatment trial of pevonedistat combined with azacitidine as the treatment of rare bone marrow cancer failed
Time of Update: 2021-09-19
It is reported that the test was carried out in patients with high-risk myelodysplastic syndrome (HR-MDS), chronic monocytic leukemia (CMML), and hypomyelocytic acute myeloid leukemia (LB-AML), and evaluated the combination of pevonedistat and azacitidine Whether first-line treatment can improve EFS compared with azacitidine alone .
Zhongke 100,000 tons of PBAT signed in Hunan
Time of Update: 2021-09-19
On August 20th, Zhongke said that it plans to invest 600 million yuan to build a biodegradable resin project with an annual production capacity of 100,000 tons in the first phase and 400,000 tons in the second phase .
The first batch of Wuhan-produced inactivated vaccines for the new crown is officially launched, and the annual output can reach 100 million doses
Time of Update: 2021-07-23
Wuhan Institute of Biological Products has built a biosafety workshop for the new crown inactivated vaccine.
It is understood that since July 16, 2020, China Bio-Wuhan has carried out the "New Coronary Inactivated Vaccine Phase III Clinical Trial" in many countries including the United Arab Emirates.
Li's drug company's anti-PD-L1 monoclonal antibody was approved for Phase 3 clinical trials
Time of Update: 2021-07-19
According to the announcement, socazolimab has previously completed three phase 1 single-drug clinical trials: (1) recurrent or metastatic cervical cancer; (2) advanced urinary epithelial cancer; and (3) high-grade osteosarcoma About SOCAZOLIMAB Socazolimab is a fully human anti-PD-L1 monoclonal antibody screened using Sorrento's patented G-MAB™ library platform .
The pediatric Chinese patent medicine market has shrunk TOP10 products who are the most resistant to stress
Time of Update: 2021-06-11
Figure 1: The share of the seven subcategories of pediatric Chinese patent medicines in 2020 (unit: %) Source: Mi Nei Net Database In terms of subcategories, pediatric cold medications and pediatric cough and expectorant medications are the two subcategories with the largest proportions, both at the terminals of public medical institutions in China and physical pharmacies in cities in China, but they are also the two most affected by the epidemic.
The detailed data of the Phase 3 clinical trial of Kexing inactivated vaccine is announced, and the protective effect can be observed 14 days after the first dose of the vaccine
Time of Update: 2021-04-18
The results of this test showed that the protective effect of two doses of CoronaVac on symptomatic COVID-19 reached 50.
7%, and the protective effect of moderate to severe cases and severe COVID-19 reached 100%.
Listing sold out of goods Green Valley nine issue one has been repeatedly questioned! Lilly Roche and other MNCs have folded
Time of Update: 2021-03-12
The pharmaceutical giants' former foray into the alzheimer's field is undoubtedly a big unsoponsed market demand, new drug research and development is not easy, and obviously there is a huge investme